Cenduit Introduces New Clinical Trial Supply Simulation and Forecasting Service

Cenduit Introduces New Clinical Trial Supply Simulation and Forecasting Service

SCORR Marketing

[email protected]

has introduced a new that will enable clinical trial sites to better plan and control supplies for their patients. When integrated with Cenduit’s interactive response technology (IRT) services, the new service will give sponsors complete confidence in their clinical supply chain.

“Clinical trials are more complex than ever and a robust and reliable clinical trial supply strategy is vital to study success,” said Jogin Desai, Cenduit chief executive officer. “The simulation and forecasting models, integrated with the and services inherent in our IRT systems, allow the complete coordination of procurement, packaging and logistics, with supply requirements from the sites themselves continuously factored in.”

Desai said the new system helps further minimize the risk of drug supply overage and drug outages at sites and accelerates drug development through increased supply chain productivity. The system also allows clinical trial supply coordinators to test different supply scenarios before implementing them, and to identify in advance the risks associated with any supply strategy.

“By integrating forecasting and simulation parameters into the IRT system, patients will receive the right treatment on time, every time and at the lowest cost,” Desai said.

provides interactive response technology (IRT) - driven services for clinical trials around the world. Cenduit’s IRT solutions deliver optimized clinical supply chain management and facilitate precise control over patient randomization and drug administration to enable more efficient, compliant trials. With expert personnel located around the globe, Cenduit’s unprecedented level of support currently covers more than 16,000 sites in more than 100 countries. Focus on trials, not tribulations, with Cenduit. For more information or to connect with Cenduit, visit .

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.